Posted by Michael Wonder on 06 Jun 2023
GSK receives US FDA file acceptance for Jemperli (dostarlimab) plus chemotherapy for the treatment of dMMR/MSI-H primary advanced or recurrent endometrial cancer
6 June 2023 - Submission accepted for Priority Review.
GSK today announced the US FDA accepted the supplemental biologics license application for Jemperli (dostarlimab) in combination with chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer.
